bimatoprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
prostaglandins	371	155206-00-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lumigan bimatoprost prostamide	A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. Molecular weight: 415.57 Formula: C25H37NO4 CLOGP: 1.75 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 89.79 ALOGS: -4.35 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lumigan
bimatoprost
prostamide

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Molecular weight: 415.57
Formula: C25H37NO4
CLOGP: 1.75
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 89.79
ALOGS: -4.35
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.80 mg/mL	Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution)	0.67 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	25 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.12 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.45 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 8, 2002	EMA
March 16, 2001	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	2306.72	17.83	634	15319	24510	63448559
Eye irritation	1816.36	17.83	511	15442	21460	63451609
Erythema of eyelid	1777.03	17.83	331	15622	1955	63471114
Madarosis	1714.97	17.83	337	15616	2744	63470325
Eye pruritus	1361.14	17.83	394	15559	18277	63454792
Eyelids pruritus	987.21	17.83	181	15772	961	63472108
Eyelid irritation	734.98	17.83	126	15827	417	63472652
Eye swelling	593.99	17.83	224	15729	23694	63449375
Eyelid oedema	558.77	17.83	174	15779	10305	63462764
Treatment failure	413.63	17.83	365	15588	198678	63274391
Eye pain	372.70	17.83	178	15775	33676	63439393
Intraocular pressure increased	349.56	17.83	107	15846	5971	63467098
Blepharal pigmentation	299.13	17.83	44	15909	28	63473041
Trichorrhexis	243.32	17.83	58	15895	1231	63471838
Dry eye	223.87	17.83	135	15818	40626	63432443
Skin hyperpigmentation	220.67	17.83	75	15878	5846	63467223
Eye discharge	218.93	17.83	75	15878	5988	63467081
Vision blurred	199.15	17.83	173	15780	91751	63381318
Lacrimation increased	189.65	17.83	96	15857	20535	63452534
Eyelid pain	176.49	17.83	35	15918	297	63472772
Blepharitis	169.60	17.83	51	15902	2674	63470395
Drug ineffective	168.98	17.83	608	15345	1044157	62428912
Scleral hyperaemia	155.80	17.83	31	15922	268	63472801
Growth of eyelashes	152.44	17.83	29	15924	193	63472876
Eyelid exfoliation	146.56	17.83	27	15926	147	63472922
Product administered at inappropriate site	133.66	17.83	44	15909	3105	63469964
Wrong technique in product usage process	130.23	17.83	115	15838	62225	63410844
Inappropriate schedule of product administration	128.37	17.83	144	15809	103821	63369248
Eyelash discolouration	125.21	17.83	20	15933	36	63473033
Swelling of eyelid	113.76	17.83	39	15914	3117	63469952
Foreign body sensation in eyes	110.25	17.83	35	15918	2199	63470870
Iris hyperpigmentation	107.38	17.83	17	15936	28	63473041
Corneal endothelial cell loss	106.61	17.83	15	15938	3	63473066
Eyelid thickening	98.04	17.83	17	15936	61	63473008
Hypersensitivity	94.18	17.83	219	15734	292466	63180603
Visual acuity reduced	89.13	17.83	60	15893	21766	63451303
Erythema	87.98	17.83	158	15795	175593	63297476
Eyelid rash	79.24	17.83	16	15937	150	63472919
Abnormal sensation in eye	76.49	17.83	25	15928	1724	63471345
Ocular discomfort	74.63	17.83	31	15922	4202	63468867
Eye colour change	70.18	17.83	16	15937	277	63472792
Skin irritation	65.97	17.83	37	15916	9704	63463365
Hair growth abnormal	63.46	17.83	25	15928	2956	63470113
Eyelid margin crusting	62.15	17.83	19	15934	1053	63472016
Corneal oedema	59.91	17.83	20	15933	1473	63471596
Skin discolouration	56.48	17.83	58	15895	37770	63435299
Product delivery mechanism issue	56.23	17.83	14	15939	358	63472711
Glaucoma	54.33	17.83	42	15911	18863	63454206
Hordeolum	54.32	17.83	23	15930	3269	63469800
Product packaging quantity issue	53.72	17.83	18	15935	1341	63471728
Incorrect dose administered	52.68	17.83	70	15883	59898	63413171
Eyelid disorder	51.99	17.83	19	15934	1830	63471239
Expired product administered	51.67	17.83	27	15926	6154	63466915
Iris disorder	50.83	17.83	10	15943	81	63472988
Lid sulcus deepened	50.62	17.83	10	15943	83	63472986
Eyelid skin dryness	49.98	17.83	11	15942	161	63472908
Product quality issue	49.98	17.83	53	15900	35812	63437257
Eyelash changes	47.86	17.83	7	15946	4	63473065
Cataract	47.67	17.83	65	15888	56988	63416081
Dark circles under eyes	45.60	17.83	13	15940	564	63472505
Eye infection	43.94	17.83	31	15922	12114	63460955
Joint swelling	43.68	17.83	14	15939	327652	63145417
Maternal exposure during pregnancy	43.64	17.83	3	15950	220059	63253010
Visual impairment	42.28	17.83	76	15877	84370	63388699
Eye inflammation	39.91	17.83	22	15931	5577	63467492
Body height decreased	39.45	17.83	27	15926	10051	63463018
Corneal opacity	38.15	17.83	12	15941	731	63472338
Conjunctival hyperaemia	37.20	17.83	16	15937	2363	63470706
Conjunctivitis	36.82	17.83	35	15918	20761	63452308
Periorbital fat atrophy	36.45	17.83	5	15948	0	63473069
Eyelash hyperpigmentation	36.45	17.83	5	15948	0	63473069
Intraocular pressure decreased	36.42	17.83	8	15945	116	63472953
Cystoid macular oedema	36.33	17.83	14	15939	1561	63471508
Systemic lupus erythematosus	35.81	17.83	5	15948	208913	63264156
Eye allergy	34.66	17.83	12	15941	987	63472082
Therapeutic product effect decreased	34.62	17.83	4	15949	193183	63279886
Product container issue	34.57	17.83	14	15939	1779	63471290
Trichiasis	34.35	17.83	7	15946	69	63473000
Eye disorder	34.25	17.83	35	15918	22650	63450419
Pyrexia	33.99	17.83	41	15912	470437	63002632
Glossodynia	33.88	17.83	3	15950	178873	63294196
Application site discolouration	32.95	17.83	11	15942	810	63472259
Condition aggravated	32.42	17.83	32	15921	402185	63070884
Eyelid sensory disorder	32.30	17.83	7	15946	95	63472974
Toxicity to various agents	32.17	17.83	11	15942	247239	63225830
Application site pain	31.38	17.83	17	15936	4165	63468904
Conjunctival scar	31.15	17.83	6	15947	43	63473026
Asthenopia	30.99	17.83	14	15939	2323	63470746
Scleral discolouration	30.65	17.83	9	15944	434	63472635
Contraindicated product administered	29.51	17.83	9	15944	217639	63255430
Application site pruritus	29.35	17.83	16	15937	3968	63469101
Prostaglandin analogue periorbitopathy	29.16	17.83	4	15949	0	63473069
Eyelid vascular disorder	29.16	17.83	4	15949	0	63473069
Hyperplastic cholecystopathy	29.03	17.83	7	15946	156	63472913
Photophobia	28.07	17.83	28	15925	17607	63455462
Drug intolerance	27.94	17.83	22	15931	308639	63164430
Pain	27.48	17.83	95	15858	740533	62732536
Arthralgia	27.03	17.83	65	15888	569645	62903424
Application site erythema	26.47	17.83	16	15937	4819	63468250
Exposure during pregnancy	26.01	17.83	4	15949	155543	63317526
Application site irritation	24.86	17.83	11	15942	1739	63471330
Visual field defect	24.32	17.83	17	15936	6544	63466525
Infusion related reaction	24.17	17.83	16	15937	245505	63227564
Accidental exposure to product	24.07	17.83	32	15921	27373	63445696
Product container seal issue	23.93	17.83	6	15947	158	63472911
Alopecia	23.73	17.83	30	15923	337506	63135563
Punctate keratitis	23.66	17.83	8	15945	613	63472456
Wound	23.53	17.83	6	15947	163257	63309812
Nausea	23.45	17.83	123	15830	854348	62618721
Milia	23.34	17.83	5	15948	64	63473005
General physical health deterioration	22.87	17.83	11	15942	201391	63271678
Arthropathy	22.18	17.83	16	15937	234776	63238293
Product odour abnormal	21.20	17.83	9	15944	1287	63471782
Product use issue	20.86	17.83	15	15938	220505	63252564
Pericarditis	20.64	17.83	4	15949	131575	63341494
Ulcerative keratitis	20.29	17.83	11	15942	2699	63470370
Periorbital disorder	20.06	17.83	4	15949	35	63473034
Therapeutic response decreased	19.65	17.83	46	15907	61479	63411590
Discomfort	19.22	17.83	9	15944	167365	63305704
Therapeutic product effect incomplete	19.20	17.83	4	15949	125052	63348017
Thrombocytopenia	19.17	17.83	7	15946	151150	63321919
Overdose	19.14	17.83	3	15950	115075	63357994
Product physical consistency issue	18.97	17.83	7	15946	692	63472377
Intraocular pressure test abnormal	18.83	17.83	5	15948	166	63472903
Lower respiratory tract infection	18.80	17.83	5	15948	132302	63340767
Meibomianitis	18.76	17.83	4	15949	50	63473019
Eyelid ptosis	18.42	17.83	15	15938	7252	63465817
Ocular vascular disorder	18.42	17.83	6	15947	409	63472660
Breast inflammation	18.38	17.83	5	15948	182	63472887
Mobility decreased	18.35	17.83	4	15949	121155	63351914
Enophthalmos	18.34	17.83	4	15949	56	63473013
Flat anterior chamber of eye	18.34	17.83	4	15949	56	63473013
Breast haemorrhage	18.13	17.83	5	15948	192	63472877

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Treatment failure	527.18	18.46	220	5598	46477	34904636
Intraocular pressure increased	331.09	18.46	91	5727	5292	34945821
Eye irritation	173.43	18.46	60	5758	7501	34943612
Ocular hyperaemia	152.63	18.46	61	5757	11391	34939722
Eye pain	104.60	18.46	49	5769	13413	34937700
Visual acuity reduced	93.23	18.46	48	5770	16101	34935012
Vision blurred	57.42	18.46	53	5765	45910	34905203
Conjunctival hyperaemia	54.79	18.46	19	5799	2383	34948730
Enophthalmos	54.70	18.46	8	5810	11	34951102
Corneal endothelial cell loss	53.91	18.46	7	5811	0	34951113
Growth of eyelashes	53.71	18.46	10	5808	93	34951020
Corneal oedema	48.25	18.46	15	5803	1336	34949777
Glaucoma	47.09	18.46	23	5795	6889	34944224
Blepharal pigmentation	46.21	18.46	6	5812	0	34951113
Choroidal detachment	44.67	18.46	11	5807	411	34950702
Cataract	44.46	18.46	36	5782	26150	34924963
Eye pruritus	39.59	18.46	21	5797	7468	34943645
Scleral hyperaemia	37.61	18.46	7	5811	65	34951048
Visual field defect	36.91	18.46	17	5801	4466	34946647
Corneal opacity	36.41	18.46	10	5808	576	34950537
Erythema of eyelid	35.89	18.46	11	5807	934	34950179
Fat tissue decreased	35.45	18.46	7	5811	91	34951022
Lacrimation increased	31.83	18.46	19	5799	8463	34942650
Foreign body sensation in eyes	31.13	18.46	9	5809	625	34950488
Punctate keratitis	30.73	18.46	8	5810	375	34950738
Instillation site pain	29.47	18.46	6	5812	92	34951021
Cardioactive drug level increased	29.45	18.46	11	5807	1706	34949407
Eyelid irritation	28.06	18.46	6	5812	118	34950995
Iritis	27.55	18.46	10	5808	1431	34949682
Corneal neovascularisation	27.00	18.46	5	5813	45	34951068
Corneal infiltrates	26.50	18.46	6	5812	155	34950958
Blindness	26.27	18.46	21	5797	14965	34936148
Lid sulcus deepened	25.40	18.46	5	5813	64	34951049
Intraocular pressure fluctuation	24.79	18.46	4	5814	14	34951099
Ocular surface disease	24.66	18.46	5	5813	75	34951038
Keratitis interstitial	23.81	18.46	4	5814	19	34951094
Corneal erosion	23.65	18.46	5	5813	93	34951020
Complication of device insertion	23.30	18.46	5	5813	100	34951013
Visual impairment	21.33	18.46	28	5790	35774	34915339
Corneal pigmentation	21.03	18.46	3	5815	3	34951110
Macular oedema	20.76	18.46	10	5808	2904	34948209
Visual acuity tests abnormal	20.40	18.46	4	5814	50	34951063
Eye disorder	20.31	18.46	15	5803	9513	34941600
Blepharitis	20.28	18.46	8	5810	1437	34949676
Product administered at inappropriate site	20.05	18.46	9	5809	2227	34948886
Product packaging quantity issue	19.85	18.46	7	5811	922	34950191
Corneal disorder	19.81	18.46	7	5811	927	34950186
Eye swelling	19.67	18.46	15	5803	9980	34941133
Aortic stenosis	19.64	18.46	11	5807	4347	34946766
Intraocular pressure decreased	19.20	18.46	4	5814	69	34951044
Computerised tomogram head abnormal	18.59	18.46	4	5814	81	34951032

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ocular hyperaemia	1212.83	15.03	370	14529	27836	79701653
Eye irritation	1078.42	15.03	315	14584	20366	79709123
Erythema of eyelid	1032.43	15.03	204	14695	2366	79727123
Madarosis	751.23	15.03	159	14740	2643	79726846
Eye pruritus	671.77	15.03	219	14680	20351	79709138
Eyelids pruritus	623.27	15.03	114	14785	839	79728650
Eyelid irritation	446.55	15.03	77	14822	384	79729105
Intraocular pressure increased	395.88	15.03	121	14778	9084	79720405
Eyelid oedema	372.05	15.03	127	14772	13560	79715929
Eye swelling	307.03	15.03	132	14767	26336	79703153
Eye pain	256.95	15.03	130	14769	37448	79692041
Blepharal pigmentation	203.64	15.03	29	14870	22	79729467
Vision blurred	174.21	15.03	150	14749	105748	79623741
Lacrimation increased	139.81	15.03	73	14826	22404	79707085
Growth of eyelashes	137.96	15.03	25	14874	173	79729316
Dry eye	133.04	15.03	84	14815	36847	79692642
Visual acuity reduced	131.80	15.03	77	14822	29392	79700097
Trichorrhexis	128.39	15.03	30	14869	793	79728696
Skin hyperpigmentation	127.91	15.03	49	14850	7254	79722235
Eye discharge	118.42	15.03	44	14855	5990	79723499
Blepharitis	117.15	15.03	37	14862	3087	79726402
Scleral hyperaemia	108.47	15.03	22	14877	292	79729197
Eyelid exfoliation	98.17	15.03	18	14881	134	79729355
Product administered at inappropriate site	89.28	15.03	32	14867	3933	79725556
Eyelid pain	88.41	15.03	19	14880	339	79729150
Conjunctival hyperaemia	75.10	15.03	29	14870	4384	79725105
Foreign body sensation in eyes	74.51	15.03	24	14875	2133	79727356
Iris hyperpigmentation	71.04	15.03	11	14888	23	79729466
Wrong technique in product usage process	69.30	15.03	77	14822	73798	79655691
Abnormal sensation in eye	68.76	15.03	22	14877	1913	79727576
Eyelash discolouration	68.43	15.03	12	14887	67	79729422
Glaucoma	63.86	15.03	42	14857	19719	79709770
Body height decreased	62.46	15.03	31	14868	8549	79720940
Cataract	62.17	15.03	67	14832	62053	79667436
Enophthalmos	61.63	15.03	11	14888	69	79729420
Inappropriate schedule of product administration	58.43	15.03	96	14803	133532	79595957
Erythema	56.35	15.03	127	14772	223163	79506326
Eyelid thickening	56.27	15.03	10	14889	61	79729428
Corneal oedema	54.70	15.03	20	14879	2600	79726889
Visual field defect	49.53	15.03	27	14872	9018	79720471
Ocular discomfort	45.38	15.03	21	14878	4962	79724527
Fat tissue decreased	44.47	15.03	9	14890	118	79729371
Choroidal detachment	43.50	15.03	12	14887	624	79728865
Corneal endothelial cell loss	41.36	15.03	6	14893	6	79729483
Eyelid disorder	40.93	15.03	15	14884	1963	79727526
Hair growth abnormal	39.35	15.03	16	14883	2768	79726721
Ocular surface disease	38.85	15.03	8	14891	115	79729374
Punctate keratitis	38.31	15.03	12	14887	974	79728515
Swelling of eyelid	37.66	15.03	17	14882	3794	79725695
Lid sulcus deepened	36.55	15.03	8	14891	156	79729333
Blindness	34.51	15.03	34	14865	28349	79701140
Skin irritation	34.17	15.03	23	14876	11217	79718272
Eye colour change	33.96	15.03	9	14890	402	79729087
Eyelid margin crusting	33.40	15.03	11	14888	1048	79728441
Periorbital disorder	32.02	15.03	6	14893	51	79729438
Eye inflammation	31.98	15.03	18	14881	6395	79723094
Ulcerative keratitis	31.90	15.03	15	14884	3674	79725815
Drug ineffective	31.62	15.03	324	14575	1080589	78648900
Eye infection	30.63	15.03	22	14877	11898	79717591
Conjunctivitis	29.78	15.03	30	14869	25685	79703804
Conjunctival scar	29.10	15.03	7	14892	210	79729279
Macular oedema	29.03	15.03	16	14883	5458	79724031
Skin discolouration	28.94	15.03	37	14862	40997	79688492
Instillation site pain	28.93	15.03	9	14890	714	79728775
Hyperplastic cholecystopathy	28.91	15.03	7	14892	216	79729273
Toxicity to various agents	27.55	15.03	23	14876	421517	79307972
Eyelash thickening	26.30	15.03	4	14895	7	79729482
Visual impairment	26.15	15.03	55	14844	92076	79637413
Flat anterior chamber of eye	25.77	15.03	6	14893	156	79729333
Eyelid rash	25.41	15.03	6	14893	166	79729323
Expired product administered	25.28	15.03	16	14883	7035	79722454
Corneal erosion	25.21	15.03	7	14892	373	79729116
Intraocular pressure decreased	25.07	15.03	6	14893	176	79729313
Prostaglandin analogue periorbitopathy	24.80	15.03	4	14895	12	79729477
Intraocular pressure fluctuation	24.67	15.03	5	14894	66	79729423
Implantation complication	23.91	15.03	4	14895	16	79729473
Product container issue	23.82	15.03	9	14890	1282	79728207
Eyelid sensory disorder	23.78	15.03	5	14894	80	79729409
Application site discolouration	23.39	15.03	8	14891	856	79728633
Trichiasis	22.92	15.03	5	14894	96	79729393
Periorbital fat atrophy	22.76	15.03	3	14896	0	79729489
Eyelid vascular disorder	22.76	15.03	3	14896	0	79729489
Eyelash hyperpigmentation	22.76	15.03	3	14896	0	79729489
Visual acuity tests abnormal	21.98	15.03	5	14894	117	79729372
Corneal disorder	21.94	15.03	10	14889	2281	79727208
Corneal infiltrates	21.90	15.03	6	14893	304	79729185
Asthenopia	21.39	15.03	10	14889	2417	79727072
Iris disorder	20.80	15.03	6	14893	367	79729122
Eye haemorrhage	20.58	15.03	16	14883	9741	79719748
Fall	20.25	15.03	158	14741	487471	79242018
Cardioactive drug level increased	20.11	15.03	11	14888	3698	79725791
Iritis	19.71	15.03	11	14888	3844	79725645
Condition aggravated	19.71	15.03	40	14859	501084	79228405
Treatment failure	19.58	15.03	4	14895	170482	79559007
Angle closure glaucoma	19.45	15.03	10	14889	2966	79726523
Eyelid skin dryness	19.21	15.03	5	14894	208	79729281
Therapeutic product effect decreased	18.50	15.03	4	14895	163859	79565630
Corneal opacity	18.42	15.03	7	14892	1013	79728476
Uveitis	18.33	15.03	19	14880	16811	79712678
Meibomianitis	18.18	15.03	4	14895	80	79729409
Incorrect dose administered	17.54	15.03	42	14857	76588	79652901
Extrasystoles	17.49	15.03	13	14886	7406	79722083
Choroidal effusion	17.28	15.03	6	14893	671	79728818
Application site pruritus	17.14	15.03	10	14889	3800	79725689
Product quality issue	17.04	15.03	26	14873	33914	79695575
Macular fibrosis	16.90	15.03	6	14893	717	79728772
Photophobia	16.87	15.03	20	14879	20508	79708981
Computerised tomogram head abnormal	16.86	15.03	4	14895	113	79729376
Eyelid ptosis	16.82	15.03	15	14884	11029	79718460
Instillation site reaction	16.68	15.03	5	14894	350	79729139
Blindness unilateral	16.41	15.03	13	14886	8133	79721356
Eye disorder	16.33	15.03	21	14878	23391	79706098
Arcus lipoides	16.28	15.03	3	14896	23	79729466
Joint swelling	16.22	15.03	18	14881	288628	79440861
Eosinophil count	16.09	15.03	4	14895	138	79729351
Intraocular pressure test abnormal	16.06	15.03	4	14895	139	79729350
Keratitis interstitial	15.96	15.03	3	14896	26	79729463
Hordeolum	15.92	15.03	9	14890	3224	79726265
General physical health deterioration	15.65	15.03	17	14882	275221	79454268
Corneal neovascularisation	15.52	15.03	4	14895	160	79729329
Breast haemorrhage	15.47	15.03	4	14895	162	79729327
Inflammatory carcinoma of the breast	15.23	15.03	3	14896	34	79729455
Breast inflammation	15.22	15.03	4	14895	173	79729316
Aortic stenosis	15.18	15.03	12	14887	7483	79722006

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01EE03	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
FDA CS	M0017805	Prostaglandins
FDA EPC	N0000175454	Prostaglandin Analog
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:39456	antiglaucoma agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Hypertrichosis of eyelid	indication	79830009	DOID:11669
Open-angle glaucoma	indication	84494001	DOID:1067
Aphakia	contraindication	24010005
Macular retinal edema	contraindication	37231002	DOID:4449
Iritis	contraindication	65074000	DOID:1406
Pseudophakia	contraindication	95217000
Uveitis	contraindication	128473001	DOID:13141
Liver function tests abnormal	contraindication	166603001
Cystoid macular edema	contraindication	193387007	DOID:4447
Disease of liver	contraindication	235856003	DOID:409

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.89	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	8263054	Jan. 15, 2023	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	8632760	Jan. 15, 2023	METHOD OF INCREASING EYELASH GROWTH
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	8758733	Jan. 15, 2023	METHOD OF INCREASING EYELASH GROWTH
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	8986715	Jan. 15, 2023	METHOD OF INCREASING HAIR GROWTH
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	9216183	Jan. 15, 2023	METHOD OF INCREASING EYELASH GROWTH
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	9226931	Jan. 15, 2023	METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	8038988	Aug. 25, 2023	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
10MCG	DURYSTA	ABBVIE	N211911	March 4, 2020	RX	IMPLANT	OPHTHALMIC	10398707	April 30, 2024	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	8101161	May 25, 2024	METHOD OF INCREASING HAIR GROWTH
0.03%	LATISSE	ABBVIE	N022369	Dec. 24, 2008	RX	SOLUTION/DROPS	TOPICAL	8101161	May 25, 2024	METHOD OF STIMULATING HAIR GROWTH
10MCG	DURYSTA	ABBVIE	N211911	March 4, 2020	RX	IMPLANT	OPHTHALMIC	8673341	Feb. 19, 2025	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	8299118	March 16, 2025	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	8309605	March 16, 2025	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	8309605	March 16, 2025	METHOD OF TREATING GLAUCOMA IN A PATIENT
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	8338479	March 16, 2025	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	8524777	March 16, 2025	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	8586630	March 16, 2025	A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	8772338	March 16, 2025	A METHOD OF LOWERING INTRAOCULAR PRESSURE
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	9155716	March 16, 2025	A METHOD OF LOWERING INTRAOCULAR PRESSURE
0.01%	LUMIGAN	ABBVIE	N022184	Aug. 31, 2010	RX	SOLUTION/DROPS	OPHTHALMIC	9241918	March 16, 2025	METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
10MCG	DURYSTA	ABBVIE	N211911	March 4, 2020	RX	IMPLANT	OPHTHALMIC	8206737	April 7, 2027	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
10MCG	DURYSTA	ABBVIE	N211911	March 4, 2020	RX	IMPLANT	OPHTHALMIC	9980974	Oct. 31, 2034	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MCG	DURYSTA	ABBVIE	N211911	March 4, 2020	RX	IMPLANT	OPHTHALMIC	March 4, 2023	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Prostaglandin F2-alpha receptor	GPCR	P43088	PF2R_HUMAN	AGONIST	Ki	5.30		WOMBAT-PK	CHEMBL
Aldo-keto reductase family 1 member C3	Enzyme	P42330	AK1C3_HUMAN		IC50	5.30		CHEMBL

External reference:

ID	Source
D02724	KEGG_DRUG
283810	RXNORM
C0937917	UMLSCUI
CHEBI:51230	CHEBI
15M	PDB_CHEM_ID
CHEMBL1200963	ChEMBL_ID
D000069580	MESH_DESCRIPTOR_UI
DB00905	DRUGBANK_ID
5311027	PUBCHEM_CID
1958	IUPHAR_LIGAND_ID
8035	INN_ID
QXS94885MZ	UNII
15937	MMSL
234008	MMSL
41256	MMSL
129492005	SNOMEDCT_US
395300006	SNOMEDCT_US
4021262	VANDF
009115	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LUMIGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0023-3205	SOLUTION/ DROPS	0.10 mg	OPHTHALMIC	NDA	25 sections
LUMIGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0023-3205	SOLUTION/ DROPS	0.10 mg	OPHTHALMIC	NDA	25 sections
LATISSE	HUMAN PRESCRIPTION DRUG LABEL	1	0023-3616	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	NDA	25 sections
LATISSE	HUMAN PRESCRIPTION DRUG LABEL	1	0023-3616	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	NDA	25 sections
LUMIGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9187	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	Export only	1 sections
DURYSTA	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9652	IMPLANT	10 ug	INTRACAMERAL	NDA	23 sections
DURYSTA	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9652	IMPLANT	10 ug	INTRACAMERAL	NDA	23 sections
DURYSTA	HUMAN PRESCRIPTION DRUG LABEL	1	0023-9652	IMPLANT	10 ug	INTRACAMERAL	NDA	23 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6206	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6206	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6206	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
BIMATOPROST	HUMAN PRESCRIPTION DRUG LABEL	1	42571-128	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	24 sections
BIMATOPROST	HUMAN PRESCRIPTION DRUG LABEL	1	42571-128	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	24 sections
Bimatoprost	Human Prescription Drug Label	1	46708-507	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
bimatoprost	Human Prescription Drug Label	1	46708-511	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	22 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	50383-908	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	50383-908	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	50383-912	SOLUTION	3 ug	TOPICAL	ANDA	22 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	50383-912	SOLUTION	3 ug	TOPICAL	ANDA	22 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	50383-912	SOLUTION	3 ug	TOPICAL	ANDA	22 sections
LUMIGAN	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4575	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	NDA	25 sections
LUMIGAN	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6304	SOLUTION/ DROPS	0.10 mg	OPHTHALMIC	NDA	25 sections
bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	57297-429	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0583	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	24 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0583	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	24 sections
Bimatoprost	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0583	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	24 sections
Bimatoprost	Human Prescription Drug Label	1	62332-507	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
Bimatoprost	Human Prescription Drug Label	1	62332-507	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
Bimatoprost	Human Prescription Drug Label	1	62332-507	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	23 sections
bimatoprost	Human Prescription Drug Label	1	62332-511	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	22 sections